Orexigen Therapeutics says it will post mid stage study data for Empatic before market opens
By APWednesday, September 30, 2009
Orexigen to report obesity drug data Wednesday
SAN DIEGO — Orexigen Therapeutics Inc. said it will report results from a midstage study of its obesity drug candidate Empatic on Wednesday morning.
Orexigen plans to hold a conference call to discuss the results at 8:30 a.m. EDT, following its announcement. The company is also developing Contrave as an obesity drug candidate. It reported results from three successful late stage trials of Contrave in July.
Shares of Orexigen rose 52 cents, or 5.3 percent, to $10.35 in aftermarket trading. The stock edged up to $9.83 during the day session.
Filed under: Obesity
Tags: California, Diagnosis And Treatment, Diseases And Conditions, Health Care Industry, Medical Research, Medication, North America, Products And Services, San Diego, United States
Tags: California, Diagnosis And Treatment, Diseases And Conditions, Health Care Industry, Medical Research, Medication, North America, Products And Services, San Diego, United States
Discussion
|
January 7, 2010: 3:38 pm
I think Orexigen should focus more on Contrave before getting us all hyped up about Empatic. |
YOUR VIEW POINT
John